Medical Services Advisory Committee - Applications scheduled to be considered

• 1734 - Intravascular lithotripsy for the treatment of moderately or severely calcified peripheral artery disease
• 1749 - Insertion of durable left ventricular assist device for use as destination therapy
• 1744 – 177Lutetium(nca)-DOTA-octreotate treatment for advanced neuroendocrine tumours and other high somatostatin receptor expressing tumours
• 1750 - Testing of tumour tissue to detect IDH1 mutations in patients with cholangiocarcinoma to determine eligibility for ivosidenib on the Pharmaceutical Benefits Scheme
• 1760 - DPYD genotyping to predict fluoropyrimidine-induced toxicity
• 1761 - Faecal calprotectin for the monitoring of disease activity in patients with inflammatory bowel disease
• 1766 - Genetic testing to detect AKT-pathway alterations in patients with hormone receptor-positive, HER2-negative advanced breast cancer, to determine eligibility for PBS subsidised capivasertib treatment
• 1775 - Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I)

Consultation Input:

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.

It is anticipated that the above-mentioned applications will proceed to MSAC in November 2024. Consultation input closed Friday 11 October 2024.

Further information on MSAC’s consultation process is also available on the MSAC website.